Cargando…

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study

Continuous subcutaneous apomorphine infusion (CSAI) is used to treat patients with Parkinson’s disease (PD) who are experiencing motor fluctuations. However, the need to initiate this treatment during a hospital stay may restrict patients’ access to it. To assess the feasibility and benefits of init...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zagnoli, Fabien, Leblanc, Amélie, Viakhireva-Dovganyuk, Irina, Delabrousse-Mayoux, Jean-Philippe, Pouyet, Alain, Ziegler, Marc, Sogni, Laura, Patat, Marie, Bouillot, Régis, Vérin, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979890/ https://www.ncbi.nlm.nih.gov/pubmed/36862190 http://dx.doi.org/10.1007/s00702-023-02609-6

Ejemplares similares

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
por: Henriksen, Tove, et al.
Publicado: (2023)

Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice
por: Kobylecki, Christopher, et al.
Publicado: (2023)

Treating Disorders of Consciousness With Apomorphine: Protocol for a Double-Blind Randomized Controlled Trial Using Multimodal Assessments
por: Sanz, Leandro R. D., et al.
Publicado: (2019)

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
por: Auffret, Manon, et al.
Publicado: (2023)

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
por: Auffret, Manon, et al.
Publicado: (2018)

Correction to: The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
por: Auffret, Manon, et al.
Publicado: (2018)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Implantable Subcutaneous Peripheral Nerve Stimulation Improves Degenerative Ataxia
por: Alexoudi, Athanasia, et al.
Publicado: (2023)

Case Report: Successful Cerebral Revascularization and Cardiac Transplant in a 16-Year-Old Male With Syndromic BRCC3-Related Moyamoya Angiopathy
por: Pyra, Pierrick, et al.
Publicado: (2021)

Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction
por: Vlad, Benjamin, et al.
Publicado: (2023)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021)

Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
por: Putko, Brendan N., et al.
Publicado: (2020)

The Individual Ictal Fingerprint: Combining Movement Measures With Ultra Long-Term Subcutaneous EEG in People With Epilepsy
por: Kjaer, Troels W., et al.
Publicado: (2021)

Expert Perspective: Who May Benefit Most From the New Ultra Long-Term Subcutaneous EEG Monitoring?
por: Pathmanathan, Jay, et al.
Publicado: (2022)

Local subcutaneous lidocaine injection for the treatment of complex regional pain syndrome: a case report and literature review
por: Su, Yaping, et al.
Publicado: (2023)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
por: Leßmann, Volkmar, et al.
Publicado: (2023)

Common network effect-patterns after monoamine reuptake inhibition in dissociated hippocampus cultures
por: Trepl, Julia, et al.
Publicado: (2022)

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
por: Isaacson, Stuart, et al.
Publicado: (2016)

Motivational learning biases are differentially modulated by genetic determinants of striatal and prefrontal dopamine function
por: Richter, Anni, et al.
Publicado: (2021)

Continuous Intraarterial Nimodipine Infusion for the Treatment of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Retrospective, Single-Center Cohort Trial
por: Kramer, Andreas, et al.
Publicado: (2022)

Apomorphine
Publicado: (1900)

Apomorphine
Publicado: (1888)

Neuroprotection of dopamine neurons by xenon against low-level excitotoxic insults is not reproduced by other noble gases
por: Le Nogue, Déborah, et al.
Publicado: (2019)

GenIDA: an international participatory database to gain knowledge on health issues related to genetic forms of neurodevelopmental disorders
por: Burger, Pauline, et al.
Publicado: (2022)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database
por: Allignol, Arthur, et al.
Publicado: (2021)

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis
por: Novotna, Martina, et al.
Publicado: (2020)

Overview of MR Image Segmentation Strategies in Neuromuscular Disorders
por: Ogier, Augustin C., et al.
Publicado: (2021)

Necrotic Ulcers Secondary to Apomorphine Infusion
por: Llamas-Osorio, Yudy, et al.
Publicado: (2021)

Editorial: Machine Learning and Decision Support in Stroke
por: Liebeskind, David S., et al.
Publicado: (2020)

Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-mortem Studies
por: Möck, E. E. Amelie, et al.
Publicado: (2021)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
por: Centonze, Diego, et al.
Publicado: (2021)

Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson’s disease patient
por: Spagnolo, Francesca, et al.
Publicado: (2021)

Blood Pressure Target in Acute Stroke to Reduce HemorrhaGe After Endovascular Therapy: The Randomized BP TARGET Study Protocol
por: Mazighi, Mikael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jnut6lg2qtpoq3lqs3c0q72q56